1. Home
  2. IMMP vs SFST Comparison

IMMP vs SFST Comparison

Compare IMMP & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.94

Market Cap

426.9M

Sector

Health Care

ML Signal

HOLD

Logo Southern First Bancshares Inc.

SFST

Southern First Bancshares Inc.

HOLD

Current Price

$55.81

Market Cap

421.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
SFST
Founded
1987
1999
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
426.9M
421.9M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
IMMP
SFST
Price
$2.94
$55.81
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$51.00
AVG Volume (30 Days)
287.8K
49.4K
Earning Date
02-26-2026
01-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
86.78
EPS
N/A
3.23
Revenue
$3,306,742.00
$109,391,000.00
Revenue This Year
$292.48
$14.65
Revenue Next Year
N/A
$20.61
P/E Ratio
N/A
$17.24
Revenue Growth
31.28
21.32
52 Week Low
$1.32
$29.14
52 Week High
$3.53
$56.73

Technical Indicators

Market Signals
Indicator
IMMP
SFST
Relative Strength Index (RSI) 58.03 66.90
Support Level $2.91 $52.01
Resistance Level $3.16 $54.10
Average True Range (ATR) 0.15 1.22
MACD -0.03 0.16
Stochastic Oscillator 41.67 96.33

Price Performance

Historical Comparison
IMMP
SFST

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.

Share on Social Networks: